Sandoz
在场
Sandoz 的所有者是 Novartis.
是其中之一......
- Forbes Global 2000 (#99);
- Fortune 500 Europe (#62);
- Global Fortune 500 (#263);
- Stoxx 600;
- Swiss market index;
- TOB Iconic 10,000.
Novartis 是一家在股票代码 NOVN (CH) 下上市的公司。
Novartis 在 38 个国家有直接业务。Novartis 拥有 73家子公司，其中包括 Advanced Accelerator Applications、Alcon 和 Alcon ANZ。
他们在：
涉及Novartis的并购和融资。
- Novartis has announced the acquisition of Chinook Therapeutics (公布2023八月14号).
- Novartis has announced the acquisition of DTx Pharma (公布2023七月18号).
- Novartis has announced the acquisition of Chinook Therapeutics (公布2023六月15号).
高管
查看带有其 155 名主要高管的组织结构图
Sandoz 搜索最多的简介
高管在Sandoz变化
- Peter Stenico 曾任 Global Platform Head, Biosimilars and Country President, Austria, 将于 20253月1 升职为 President, Region International (新闻发布的2025二月4号).
- Francisco Ballester, Head of International Region, 将于 20253月1 退休 (新闻发布的2025二月4号).
创建提醒
跟踪 Sandoz 的高管变动
药店
Novartis 拥有 1,831 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。
Popular M&A news in 药店
- Cosette Pharmaceuticals has announced the acquisition of Mayne Pharma (公布2025二月25号).
- Bain Capital 已收购 Mitsubishi Tanabe Pharma (公布2025二月12号).
- Crown Laboratories 已收购 Revance Therapeutics (公布2025二月9号).
药店 行业的其他推荐联系人
消息
Sandoz 的最新新闻稿
- All News | Sandoz
- Major Novartis investment in Slovenia reinforces commitment to largest Sandoz product and business | Sandoz
- Sandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe* | Sandoz
- Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued | Sandoz
- Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF) | Sandoz
- HEXAL launches Dimethyl fumarate HEXAL® a generic drug for Tecfidera®, in Germany, offering an economically efficient treatment option for the care of adult patients with multiple sclerosis* | Sandoz
- Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA | Sandoz
- Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030 | Sandoz
- Sandoz appoints new Board representative to global AMR Industry Alliance | Sandoz
- Sandoz launches first generic pirfenidone in US for patients with idiopathic pulmonary fibrosis, growing its respiratory portfolio | Sandoz
- View more press releases Close
